Celldex Therapeutics, Inc.
CLDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000744218
No open-market purchases or sales by Celldex Therapeutics, Inc. insiders were filed in the last 90 days; 253 institutions reported holding it in 13F filings for Q2 2026, worth $3.16B in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Celldex Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Of which not filed for Q2 2023 | Q2 2023 | Change |
|---|---|---|---|---|
| Holders | 161 | 2 | 150 | −9 |
| Shares | 49.5M | 24 | 50.2M | +685.0K (+1.4%) |
| Value | $1.78B | $468 | $1.70B | −$76.6M (−4.3%) |
2 institutions that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Celldex Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| 5AM Venture Management, LLC | 310,270 | $10.5M | 2.62% |
| Sphera Funds Management Ltd. | 160,000 | $5.43M | 1.16% |
| International Biotechnology Trust PLC | 48,099 | $1.63M | 0.50% |
| Franklin Resources Inc | 23,003 | $780.5K | 0.00% |
| Millennium Management LLC | 20,740 | $703.7K | 0.00% |
| Los Angeles Capital Management LLC | 16,026 | $543.8K | 0.00% |
| Soleus Capital Management, L.P. | 13,600 | $461.4K | 0.05% |
| Squarepoint Ops LLC | 11,719 | $397.6K | 0.00% |
| Walleye Trading LLC | 8,538 | $289.7K | 0.02% |
| ProShare Advisors LLC | 6,043 | $205.0K | 0.00% |
| Headlands Technologies LLC | 3,984 | $135.2K | 0.04% |
| HM Payson & Co | 960 | $32.6K | 0.00% |
| Simplex Trading, LLC | 491 | $16.0K | 0.00% |
| Steward Partners Investment Advisory, LLC | 400 | $13.6K | 0.00% |
| Bell Investment Advisors, Inc | 23 | $781 | 0.00% |
| Venturi Wealth Management, LLC | 5 | $170 | 0.00% |
| Northwestern Mutual Wealth Management Co | 1 | $34 | 0.00% |
Sold out (26)
Institutions that held Celldex Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
Not filed for Q2 2023 yet (2)
Institutions that held Celldex Therapeutics, Inc. at the end of Q1 2023 and haven't filed a 13F for Q2 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Harvest Group Wealth Management, LLC | 13 | $468 |
| Householder Group Estate & Retirement Specialist, LLC | 11 | $0 |